Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12793323 | 0.86 | KDM4E (0.79) | KDM4EPOLBPKMALDH1A1LMNA | |
| SCHEMBL4009309 | 0.84 | KDM4E (0.77) | KDM4EPOLBPKMALDH1A1LMNA | |
| SCHEMBL12386397 | 0.84 | KDM4E (0.77) | KDM4EPOLBPKMALDH1A1LMNA | |
| SCHEMBL5306415 | 0.84 | POLB (1.00) | KDM4EPOLBPKMALDH1A1LMNA | |
| SCHEMBL2080837 | 0.84 | KDM4E (0.77) | KDM4EPOLBPKMALDH1A1LMNA | |
| SCHEMBL6154077 | 0.84 | POLB (1.00) | KDM4EPOLBPKMALDH1A1LMNA | |
| SCHEMBL4537988 | 0.83 | SMN1; SMN2 (0.72) | KDM4EPOLBALDH1A1LMNATSHR | |
| SCHEMBL2299329 | 0.81 | KDM4E (0.71) | KDM4EPOLBPKMALDH1A1LMNA | |
| SCHEMBL12386392 | 0.81 | KDM4E (0.71) | KDM4EPOLBPKMALDH1A1LMNA | |
| SCHEMBL2297718 | 0.81 | KDM4E (0.71) | KDM4EPOLBPKMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-08-26 | — | — | US | disclosed |
| US-7709488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1670796-B1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2008-06-25 | — | — | EP | disclosed |
| US-7279488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NYCOMED GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-12-28 | — | — | US | disclosed |
| EP-1670796-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030770-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | KDM4E 2060/4885POLB 2445/4885PKM 2251/4885 |
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | KDM4E 2060/4885POLB 2445/4885PKM 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.